Updates are available Correction dated 2024-05-07
Click to view Correction: https://doi.org/10.1038/s41375-024-02274-y
-
Authors
Arends, Christopher Maximilian http://orcid.org/0000-0003-4417-4750
Kopp, Klara
Hablesreiter, Raphael http://orcid.org/0000-0002-4586-932X
Estrada, Natalia
Christen, Friederike http://orcid.org/0000-0001-8868-2533
Moll, Ute Martha
Zeillinger, Robert
Schmitt, Wolfgang Daniel http://orcid.org/0000-0002-7870-138X
Sehouli, Jalid
Kulbe, Hagen
Fleischmann, Maximilian
Ray-Coquard, Isabelle
Zeimet, Alain
Raspagliesi, Francesco
Zamagni, Claudio
Vergote, Ignace
Lorusso, Domenica
Concin, Nicole
Bullinger, Lars
Braicu, Elena Ioana
Damm, Frederik http://orcid.org/0000-0001-5553-1173
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70113643)
Deutsche Forschungsgemeinschaft (DA 1787/3-1)
- License Information
-
More Information
Article History
Received: 10 February 2024
Revised: 9 April 2024
Accepted: 10 April 2024
First Online: 18 April 2024
Change Date: 7 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-024-02274-y
Competing interests
: FD reports personal fees from AbbVie, Amgen, Astra Zeneca, Gilead, Incyte, Novartis, and Roche outside the submitted work. LB reports advisory role for Abbvie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, Servier; as well as research funding from Bayer, Jazz Pharmaceuticals. IR reports honoraria (personal) from Agenus, Blueprint, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Macrogenics, Tesaro and Clovis; honoraria (institutional) from GSK, MSD, Roche and BMS; advisory/consulting fees from Abbvie, Agenus, Advaxis, BMS, ESAÏ, Daichi, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; research grant/funding (personal) from MSD, Roche and BMS; research grant/funding (institutional) from MSD, Roche, BMS, Novartis, Astra Zeneca and Merck Sereno; travel support from Roche, MSD, AstraZeneca and GSK. IV reports consulting fees from Agenus, AstraZeneca, Bristol Myers Squibb, Eisai, Genmab, GSK, Immunogen, Karyopharm, Mersana, MSD, Molecular Partners, Novocure, Novartis, Oncoinvent, Regeneron, Seagen, Verastem Oncology, Zai Lab, Zentalis. AGZ reports personal honoraria/travel supports from AbbVie, Amgen, Astra Zeneca, Eisai, Gilead, GSK, MSD, PharmaMar, Roche, Roche-Diagnostics Austria, Sandoz, outside the submitted work. WDS reports personal fees from AstraZeneca, GlaxoSmithKline, NOGGO and Roche outside the submitted work. All other authors declare no competing interests.
